Truist analyst Robyn Karnauskas raised the firm’s price target on Merck to $118 from $106 and keeps a Buy rating on the shares after its Q4 earnings beat. The stock fell likely because of the earnings guidance miss, but the company’s Keytruda/Gardasil growth continues while its CV franchise is emerging, the analyst tells investors in a research note. The firm remains positive on Merck’s robust cash generation, solid dividend yield, and management focus on shareholder return.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRK:
- Merck says Phase 3 NRG-GY018 trial met primary endpoint of PFS
- Pharma Earnings: Q4 Hits and Misses in a Post-COVID-19 World
- Merck sees FY23 adjusted EPS $6.80-$6.95, consensus $7.36
- Merck reports Q4 adjusted EPS $1.62, consensus $1.54
- Merck’s Keytruda approved by FDA for non-small cell lung cancer treatment